RU2197966C2 - Применение ингибитора н+, к+-атфазы для лечения носовых полипов - Google Patents

Применение ингибитора н+, к+-атфазы для лечения носовых полипов Download PDF

Info

Publication number
RU2197966C2
RU2197966C2 RU99109596/14A RU99109596A RU2197966C2 RU 2197966 C2 RU2197966 C2 RU 2197966C2 RU 99109596/14 A RU99109596/14 A RU 99109596/14A RU 99109596 A RU99109596 A RU 99109596A RU 2197966 C2 RU2197966 C2 RU 2197966C2
Authority
RU
Russia
Prior art keywords
atpase inhibitor
atpase
glucocorticoid
syndrome
inhibitor
Prior art date
Application number
RU99109596/14A
Other languages
English (en)
Russian (ru)
Other versions
RU99109596A (ru
Inventor
Пер ЛИНДБЕРГ
Хоан ПИНАС-МАССО
Хорди СЕРРА-КАРРЕРАС
Ян Трофаст
Original Assignee
Астра Зенека АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астра Зенека АБ filed Critical Астра Зенека АБ
Publication of RU99109596A publication Critical patent/RU99109596A/ru
Application granted granted Critical
Publication of RU2197966C2 publication Critical patent/RU2197966C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
RU99109596/14A 1996-10-11 1997-10-01 Применение ингибитора н+, к+-атфазы для лечения носовых полипов RU2197966C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603725-4 1996-10-11
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment

Publications (2)

Publication Number Publication Date
RU99109596A RU99109596A (ru) 2001-02-20
RU2197966C2 true RU2197966C2 (ru) 2003-02-10

Family

ID=20404214

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99109596/14A RU2197966C2 (ru) 1996-10-11 1997-10-01 Применение ингибитора н+, к+-атфазы для лечения носовых полипов

Country Status (33)

Country Link
EP (1) EP0946175B1 (cg-RX-API-DMAC7.html)
JP (1) JP4100713B2 (cg-RX-API-DMAC7.html)
KR (1) KR100510812B1 (cg-RX-API-DMAC7.html)
CN (1) CN1146416C (cg-RX-API-DMAC7.html)
AR (1) AR008886A1 (cg-RX-API-DMAC7.html)
AT (1) ATE230597T1 (cg-RX-API-DMAC7.html)
AU (1) AU738310B2 (cg-RX-API-DMAC7.html)
BR (1) BR9711896A (cg-RX-API-DMAC7.html)
CA (1) CA2268305C (cg-RX-API-DMAC7.html)
CZ (1) CZ298799B6 (cg-RX-API-DMAC7.html)
DE (1) DE69718347T2 (cg-RX-API-DMAC7.html)
DK (1) DK0946175T3 (cg-RX-API-DMAC7.html)
EE (1) EE04043B1 (cg-RX-API-DMAC7.html)
ES (1) ES2188995T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0000036A3 (cg-RX-API-DMAC7.html)
ID (1) ID23692A (cg-RX-API-DMAC7.html)
IL (1) IL129324A0 (cg-RX-API-DMAC7.html)
IS (1) IS1930B (cg-RX-API-DMAC7.html)
MY (1) MY117918A (cg-RX-API-DMAC7.html)
NO (1) NO321007B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ334786A (cg-RX-API-DMAC7.html)
PL (1) PL190902B1 (cg-RX-API-DMAC7.html)
PT (1) PT946175E (cg-RX-API-DMAC7.html)
RS (1) RS49599B (cg-RX-API-DMAC7.html)
RU (1) RU2197966C2 (cg-RX-API-DMAC7.html)
SA (1) SA97180641B1 (cg-RX-API-DMAC7.html)
SE (1) SE9603725D0 (cg-RX-API-DMAC7.html)
SK (1) SK284252B6 (cg-RX-API-DMAC7.html)
TR (1) TR199900770T2 (cg-RX-API-DMAC7.html)
TW (1) TW568784B (cg-RX-API-DMAC7.html)
UA (1) UA59374C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998016228A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA978842B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2252025C1 (ru) * 2003-11-28 2005-05-20 Дальневосточный государственный медицинский университет Способ лечения избыточной грануляционной ткани гортани и трахеи

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
EP1119349B1 (en) 1998-08-18 2008-07-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
NZ514442A (en) * 1999-03-03 2003-08-29 Optinose As Nasal delivery device
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
WO2003075926A1 (en) * 2002-03-14 2003-09-18 Altana Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
NZ536918A (en) * 2002-05-07 2006-09-29 Altana Pharma Ag Combination of pantoprazole and a respiratory agent for the treatment of respiratory diseases
WO2003094967A2 (en) * 2002-05-07 2003-11-20 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005025578A1 (en) 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUND V.J. Diagnosis and treatment of nasal polyps. Brit. Med. J., 1995, 311, 1411-1414. МАЖОВСКИЙ М.Д. Лекарственные средства. - М.: Медицина, 1993, с.361. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2252025C1 (ru) * 2003-11-28 2005-05-20 Дальневосточный государственный медицинский университет Способ лечения избыточной грануляционной ткани гортани и трахеи

Also Published As

Publication number Publication date
SK38499A3 (en) 2000-03-13
ES2188995T3 (es) 2003-07-01
PL332692A1 (en) 1999-09-27
MY117918A (en) 2004-08-30
CZ122999A3 (cs) 1999-09-15
BR9711896A (pt) 1999-08-24
UA59374C2 (uk) 2003-09-15
NO991619L (no) 1999-04-06
CN1146416C (zh) 2004-04-21
DK0946175T3 (da) 2003-03-17
WO1998016228A1 (en) 1998-04-23
ATE230597T1 (de) 2003-01-15
CA2268305C (en) 2006-11-28
ZA978842B (en) 1998-04-14
SK284252B6 (sk) 2004-12-01
DE69718347T2 (de) 2003-08-28
HUP0000036A3 (en) 2003-02-28
JP4100713B2 (ja) 2008-06-11
NZ334786A (en) 2000-12-22
EP0946175A1 (en) 1999-10-06
JP2001508034A (ja) 2001-06-19
IS5021A (is) 1999-04-08
PL190902B1 (pl) 2006-02-28
CN1232397A (zh) 1999-10-20
YU16399A (sh) 2000-03-21
CA2268305A1 (en) 1998-04-23
SA97180641B1 (ar) 2005-12-18
NO991619D0 (no) 1999-04-06
AU4640997A (en) 1998-05-11
AR008886A1 (es) 2000-02-23
DE69718347D1 (de) 2003-02-13
PT946175E (pt) 2003-04-30
HUP0000036A2 (hu) 2002-05-29
IL129324A0 (en) 2000-02-17
CZ298799B6 (cs) 2008-02-06
HU0000036D0 (cg-RX-API-DMAC7.html) 2002-05-29
KR100510812B1 (ko) 2005-08-31
ID23692A (id) 2000-05-11
KR20000049046A (ko) 2000-07-25
IS1930B (is) 2004-05-18
TW568784B (en) 2004-01-01
NO321007B1 (no) 2006-02-27
EE04043B1 (et) 2003-06-16
AU738310B2 (en) 2001-09-13
EE9900118A (et) 1999-10-15
HK1022848A1 (en) 2000-08-25
RS49599B (sr) 2007-06-04
SE9603725D0 (sv) 1996-10-11
EP0946175B1 (en) 2003-01-08
TR199900770T2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
EP0946175B1 (en) USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS
US6599927B2 (en) Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
JP2008110991A (ja) 処置方法
EA008981B1 (ru) Композиция и лекарственное средство для лечения респираторных заболеваний, аллергических заболеваний, астмы и/или хронических обструктивных заболеваний легких и способ получения лекарственного средства
JP2011507895A (ja) オキシメタゾリンの増強された光安定化
RU99109596A (ru) Применение ингибитора н+, к+-атфазы для лечения носовых полипов
Brown et al. The possibility of short‐term hypothalamic‐pituitary‐adrenal axis suppression with high‐volume, high‐dose nasal mometasone irrigation in postsurgical patients with chronic rhinosinusitis
HK1022848B (en) Use of a combination of h+, k+ -atpase inhibitors and glucocorticoids in the treatment of nasal polyps
JP2006508993A (ja) ロフルミラスト及び(r,r)−ホルモテロールを含有する新規の相乗組合せ
CN1897952B (zh) 中性白细胞增多抑制剂

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20081002